The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension

Published:2019-06-05 Issue:4 Volume:14 Page:645-650
ISSN:1747-079X
Container-title:Congenital Heart Disease
language:en
Short-container-title:Congenital Heart Disease

Author:

Ruan Hongyun¹^ORCID,Zhang Yigang²,Liu Ru³,Yang Xiangjun¹

Affiliation:

1. Department of Cardiology The First Affiliated Hospital, Soochow University Suzhou China

2. Department of Cardiology Xuzhou Central Hospital Xuzhou China

3. Department of Ultrasonography Xuzhou Central Hospital Xuzhou China

Publisher

Computers, Materials and Continua (Tech Science Press)

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging,General Medicine,Surgery,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/chd.12764

Reference28 articles.

1. Pulmonary hypertension related to congenital heart disease: a call for action

2. Pulmonary Hypertension and Congenital Heart Disease

3. The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options

4. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease

5. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants;CNS Drugs;2024-02-28

2. Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD);Frontiers in Aging Neuroscience;2024-02-14

3. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension;American Journal of Cardiovascular Drugs;2023-11-09

4. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension;Expert Opinion on Investigational Drugs;2023-10-30

5. Targeting Epigenetics in Pulmonary Arterial Hypertension;Targeting Epigenetics in Inflammatory Lung Diseases;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3